Becton, Dickinson and Company (BDX) To Go Ex-Dividend on June 10th

Becton, Dickinson and Company (NYSE:BDXGet Free Report) announced a quarterly dividend on Tuesday, April 30th, RTT News reports. Stockholders of record on Monday, June 10th will be given a dividend of 0.95 per share by the medical instruments supplier on Friday, June 28th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.58%. The ex-dividend date is Monday, June 10th.

Becton, Dickinson and Company has increased its dividend by an average of 4.8% annually over the last three years. Becton, Dickinson and Company has a dividend payout ratio of 26.6% meaning its dividend is sufficiently covered by earnings. Research analysts expect Becton, Dickinson and Company to earn $14.22 per share next year, which means the company should continue to be able to cover its $3.80 annual dividend with an expected future payout ratio of 26.7%.

Becton, Dickinson and Company Trading Up 0.2 %

NYSE:BDX opened at $240.63 on Friday. The company has a market capitalization of $69.54 billion, a P/E ratio of 53.00, a P/E/G ratio of 2.10 and a beta of 0.44. The stock’s 50 day moving average price is $235.77 and its 200 day moving average price is $237.98. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. Becton, Dickinson and Company has a 52 week low of $224.00 and a 52 week high of $287.32.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter last year, the firm earned $2.86 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, research analysts forecast that Becton, Dickinson and Company will post 13.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on BDX shares. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday. Barclays upped their target price on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. Finally, The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price objective for the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average price target of $280.17.

Get Our Latest Analysis on BDX

Insider Transactions at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Roland Goette sold 3,300 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $236.73, for a total transaction of $781,209.00. Following the transaction, the executive vice president now owns 11,308 shares in the company, valued at approximately $2,676,942.84. The disclosure for this sale can be found here. Insiders sold a total of 8,597 shares of company stock worth $2,028,786 over the last three months. 0.31% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

(Get Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories

Dividend History for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.